Davide Capodanno/LinkedIn
Jan 11, 2026, 03:54
DAPT De-escalation After PCI․ Where Do We Stand Today?
Davide Capodanno, Full Professor of Cardiology at the University of Catania, shared on X:
“ DAPT after PCI remains essential, but balancing ischemic protection and bleeding risk is challenging. Over the past decade, trials have supported DAPT de-escalation—via dose reduction, drug withdrawal, or switching agents—to reduce bleeding without compromising ischemic outcomes in selected patients. Evidence for escalation is more limited. We wrote this review to summarize current data and ongoing studies. ”
Title: Dual Antiplatelet Therapy Escalation and De-escalation
Authors: Antonio Greco, Giacinto Di Leo, Simone Finocchiaro, Antonino Imbesi, Davide Capodanno
Read full article here.
Stay updated with Hemostasis Today.
-
Aug 26, 2026, 16:53Chokri Ben Lamine: Antiphospholipid Syndrome After Kidney Transplantation
-
Aug 26, 2026, 16:32Kai Rejeski: Why TP53 Mutations May Define a Higher-Risk CAR-T Population
-
Aug 26, 2026, 16:20Ons Marsit: Impact of Electroanatomical Mapping on Pentaspline Pulsed Field Ablation
-
Aug 26, 2026, 16:18Sam Mbunya: Celebrating Cyrus Njuguna Githinji’s New Leadership Role in Haemophilia Care
-
Aug 26, 2026, 15:48Melissa Hollo: Postpartum Depression is More Than the “Baby Blues”
-
Aug 26, 2026, 15:46Raghavendra Rao: The Link Between Neuropathy and Chronic Venous Disease
-
Aug 26, 2026, 15:43Laurent Bertoletti: Long Term Benefits and Safety of Rehabilitation in Pulmonary Arterial Hypertension
-
Aug 26, 2026, 15:41Tamer Hellou: Chromosome 1q Gain Signals High Long-Term Risk in AL Amyloidosis
-
Aug 26, 2026, 15:04Sequential Efgartigimod and Eltrombopag Achieve Durable Response in Refractory ITP – Platelets Journal